TP53-mediated clonal hematopoiesis confers increased risk for incident peripheral artery disease

Seyedeh M. Zekavat BS[1-4]*, Vanesa Viana-Huete PhD[5]*, Saman Doroodgar Jorshery MD MPH[3,6,7], María A. Zuriaga PhD[5], Md Mesbah Uddin PhD[3,4], Mark Trinder BS[3,4,8], Kaavya Paruchuri MD[3,4,9], Nuria Matesanz PhD[5], Virginia Zorita BS MSc[5], Alba Ferrer-Pérez BS MSc[5], Marta Amorós-Pérez BS MSc[5], Scott M. Damrauer MD[10], Christie M. Ballantyne MD[1], Abhishek Niroula PhD[3,12], Christopher J. Gibson MD[12], James Pirruccello MD[3], Gabriel Griffin MD[13], Benjamin L. Ebert MD PhD[14], Peter Libby MD PhD[7], Valentín Fuster MD PhD[5,15], Hongyu Zhao PhD[16], Marzyeh Ghassemi PhD[6,7], Pradeep Natarajan MD MMSc[3,4,7]§, Alexander G. Bick MD PhD[3,17]§, José J Fuster PhD[5,18]§, Derek Klarin MD[3,19,20]§

1. Yale School of Medicine, New Haven, CT;
2. Computational Biology & Bioinformatics Program, Yale University, New Haven, CT, USA;
3. Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA;
4. Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA;
5. Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain;
6. Department of Computer Science, University of Toronto, Toronto, Canada;
7. Department of Electrical Engineering and Computer Science and Institute for Medical and Evaluative Sciences, Massachusetts Institute of Technology, Cambridge, MA;
8. Center for Heart Lung Innovation, University of British Columbia, Vancouver;
9. Department of Medicine, Harvard Medical School, Boston, MA, USA;
10. Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
11. Center for Cardiometabolic Disease Prevention, Baylor College of Medicine, Houston, TX, USA;
12. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
13. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA;
14. Department of Hematology, Brigham and Women's Hospital, Boston, MA, USA;
15. Icahn School of Medicine at Mount Sinai, New York, NY, USA;
16. Department of Biostatistics, Yale School of Public Health, New Haven, CT;
17. Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, TN, USA;
18. CIBER en Enfermedades Cardiovasculares (CIBER-CV), Madrid, Spain;
19. Malcolm Randall VA Medical Center, Gainesville, FL;
20. Division of Vascular Surgery, University of Florida College of Medicine, FL, USA

* Co-first authors
§ Equally supervised this work

Corresponding Authors:
Jose J. Fuster, PhD
jjfuster@cnic.es
Melchor Fernández Almagro, 3
28029 - Madrid (Spain)
Tel: (+34) 914531200, ext 4304
Fax: (+34) 914531265
Twitter: @josejfuster
ORCID: 0000-0002-5970-629X

Derek Klarin, MD
derek.klarin@surgery.ufl.edu
1600 SW Archer Road, NG-45, PO Box 100128, Gainesville, FL 32610

Tel: 352-273-5485
Fax: 352-273-5515
ORCID: 0000-0002-4636-5780

______
Main Text Total word count: 3,517

Funding: P.N. is supported by a Hassenfeld Scholar Award from the Massachusetts General
Hospital, grants from the National Heart, Lung, and Blood Institute (R01HL1427,
R01HL148565, and R01HL148050), and from Fondation Leducq (TNE-18CVD04). S.M.Z is
supported by the NIH National Heart, Lung, and Blood Institute (1F30HL149180-01) and the
NIH Medical Scientist Training Program Training Grant (T32GM136651). A.G.B. is supported
by a Burroughs Wellcome Fund Career Award for Medical Scientists, a NIH Director Early
Independence Award (DP5-OD029586) and a NHLBI BioData Catalyst Fellowship (OT3
HL147154-01). J.P.P is supported by a John S LaDue Memorial Fellowship. K.P. is supported
by NIH grant 5-T32HL007208-43. J.J.F. is supported by grants RYC-2016-20026 and RTI2018-
093554-A-I00) from the Spanish "Ministerio de Ciencia e Innovación", a 2019 Leonardo Grant
for Researchers and Cultural Creators from the BBVA Foundation, the European Research Area
Network on Cardiovascular Diseases CHEMICAL (grant AC19/00133 from the "Spanish
Instituto de Salud Carlos III") and the Leducq Foundation (TNE-18CVD04). The project leading
to these results received funding from "la Caixa" Foundation (ID 100010434), under agreement
HR17-00267. The Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by
the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación and the Pro
CNIC Foundation. P.L. receives funding support from the National Heart, Lung, and Blood
Institute (1R01HL134892), the American Heart Association (18CSA34080399), the RRM
Charitable Fund, and the Simard Fund.
74
Disclosures: P.N. reported grants from Amgen during the conduct of the study and grants from
Boston Scientific; grants and personal fees from Apple; personal fees from Novartis and
Blackstone Life Sciences; and spousal employment at Vertex all outside the submitted work.
P.L. is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Baim
Institute, Beren Therapeutics, Esperion, Therapeutics, Genentech, Kancera, Kowa
Pharmaceuticals, Medimmune, Merck, Norvo Nordisk, Merck, Novartis, Pfizer, Sanofi-
Regeneron. Dr. Libby is a member of scientific advisory board for Amgen, Corvidia
Therapeutics, DalCor Pharmaceuticals, Kowa Pharmaceuticals, Olatec Therapeutics,
Medimmune, Novartis, and XBiotech, Inc. P.L.'s laboratory has received research funding in the
last 2 years from Novartis, he is on the Board of Directors of XBiotech, Inc, and has a financial
interest in Xbiotech, a company developing therapeutic human antibodies. These interests were
reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in
accordance with their conflict of interest policies. The other authors do not report any
disclosures.
89
90   **Acknowledgments:** Thanks to the participants and staff of the UK Biobank and Mass General
91   Brigham Biobank. UK Biobank analyses were conducted using Application 7089. Thanks to Dr.
92   Zeyan Liew and teaching fellow Jiajun Lu, the instructors of the causal inference course at Yale.

93
Abbreviations: CHIP, clonal hematopoiesis of indeterminate potential; PAD, peripheral artery
disease

Abstract

Background: Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate

potential (CHIP), particularly in *DNMT3A*, *TET2*, and *JAK2*, are associated with an increased

risk of hematologic malignancy, coronary artery disease, and all-cause mortality. However,

whether CHIP is associated with increased risk of peripheral artery disease (PAD) remains

unknown. In addition, chemotherapy frequently causes mutations in DNA Damage Repair

(DDR) genes *TP53* and *PPM1D*, and whether CHIP caused by somatic mutations in DDR genes

results in increased risk of atherosclerosis is unclear. We sought to test whether CHIP, and CHIP

caused by DDR genes, associates with incident peripheral artery disease (PAD) and

atherosclerosis.

Methods: We identified CHIP among 50,122 exome sequences in individuals from UK and

Mass General Brigham Biobanks and tested CHIP status (N=2,851) with incident PAD and

atherosclerosis across multiple arterial beds. To mimic the human scenario of clonal

hematopoiesis and test whether the expansion of p53-deficient hematopoietic cells contributes to

atherosclerosis, a competitive bone marrow transplantation (BMT) strategy was used to generate

atherosclerosis-prone *Ldlr*-/- chimeric mice carrying 20% *Trp53*-/- hematopoietic cells (20%

KO-BMT mice). We then evaluated aortic plaque burden and plaque macrophage accumulation

12 weeks after grafting.

Results: CHIP associated with incident PAD (HR 1.7; $P=2.2 \times 10^{-5}$) and atherosclerosis in

multiple beds (HR 1.3; $P=9.7 \times 10^{-5}$), with increased risk among individuals with DDR CHIP (HR

2.0; P=0.0084). Among atherosclerosis-prone *Ldlr* null mice, the p53 -/- 20% KO-BMT mice

demonstrated increased aortic plaque size (p=0.013) and accumulation of p53-/- plaque

macrophages (P<0.001), driven by an abundance of p53-deficient plaque macrophages. The

expansion of p53-deficient cells did not affect the expression of the pro-inflammatory cytokines

IL-6 and IL-1β in the atherosclerotic aortic wall.

Conclusions: Our findings highlight the role of CHIP as a broad driver of atherosclerosis across

the entire arterial system, with evidence of increased plaque among p53 -/- 20% KO-BMT mice

via expansion of plaque macrophages. These observations provide new insight into the link

between CHIP and cardiovascular disease, and lend human genetic support to the concept that

post-cytotoxic chemotherapy patients may benefit from surveillance for atherosclerotic

conditions in addition to therapy-related myeloid neoplasms.

Abstract Word Count: 346

Key Words: somatic, atherosclerosis, clonal hematopoiesis, sequencing
130

Introduction

Peripheral artery disease (PAD) is a leading cause of cardiovascular morbidity and mortality

worldwide, and age is among its strongest risk factors. PAD associates with an extremely high

cardiovascular mortality and unmitigated can progress to limb loss[1]. The age-related acquisition

and expansion of leukemogenic mutations in hematopoietic stem cells has recently been

associated with an increased risk of hematologic malignancy, coronary artery disease, and

overall mortality[2, 3]. This phenomenon, termed clonal hematopoiesis of indeterminate potential

(CHIP), is relatively common in asymptomatic older adults, affecting at least 10% of individuals

older than 70 years of age[4]. CHIP mutations most frequently occur in epigenetic regulators

DNMT3A and *TET2,* in DNA damage repair (DDR) genes *PPM1D* and *TP53*, or cell cycle and

transcriptional regulator genes *JAK2* and *ASXL1*[5]. CHIP associates with coronary artery disease

in multiple studies[2, 6]. Whether CHIP links with increased risk of atherosclerosis in the peripheral

arterial bed (PAD) is unknown.

Here, we leveraged 50,122 whole exome sequences from two genetic biobanks (UK

Biobank [UKB], Mass General Brigham Biobank [MGBB]) and tested whether CHIP was

associated with increased risk of PAD and atherosclerosis across multiple arterial beds, and

additionally whether these associations varied by putative CHIP driver gene. Based on these

results, we then performed functional analyses in *Ldlr*-null mice transplanted with 20% *Trp53*-/-

bone marrow cells, a murine model of atherosclerosis and clonal hematopoiesis driven by *TP53*

mutations.

Methods

Cohorts and exclusion criteria

The UKB is a population-based cohort of approximately 500,000 participants recruited from

2006-2010 with existing genomic and longitudinal phenotypic data and median 10-year follow-

up[7]. Baseline assessments were conducted at 22 assessment centres across the UK with sample

collections including blood-derived DNA. Of ~49,960 individuals with WES data available, we

analyzed 37,657 participants consenting to genetic analyses after our exclusion criteria. Use of

the data was approved by the Massachusetts General Hospital Institutional Review Board

(protocol 2013P001840) and facilitated through UK Biobank Application 7089.

The MGBB contains genotypic and clinical data from >105,000 patients who consented

to broad-based research across 7 regional hospitals and median 3-year follow-up[8]. Baseline

phenotypes were ascertained from the electronic medical record and surveys. We analyzed

12,465 individuals consenting to genetic analysis after our exclusion criteria. Use of the data was

approved by the Massachusetts General Hospital Institutional Review Board (protocol

2020P000904).

Across both cohorts, we excluded individuals with prevalent hematologic cancer,

individuals without genotypic-phenotypic sex concordance, and one of each pair of 1st or 2nd

degree relatives at random. For the UKB, samples were further restricted to individuals with

Townsend deprivation index, a marker of socioeconomic status, available for analysis. Follow-up

time was defined as time from enrollment to disease diagnosis for cases, or to censorship or

death for controls.

Whole exome sequencing and CHIP calling

UKB WES were generated from whole blood-derived DNA at the Regeneron Sequencing

Center[9]. MGBB WES were generated using whole blood-derived DNA using Illumina

sequencing (mean coverage 55x). Somatic CHIP variants were detected with GATK MuTect2

software with parameters as previously described[6, 10]. Common germline variants and sequencing

artifacts were excluded as before. Samples were annotated with the presence of any CHIP if

MuTect2 identified one or more of a pre-specified list of pathogenic somatic variants, as

previously described[11, 12]. Additionally, samples were annotated with the presence of Large

CHIP (variant allele frequency >10%), as larger CHIP clones have previously been more

strongly associated with adverse clinical outcomes[6].

Phenotype definitions

Across both UKB and MGBB, PAD was defined by grouping together ICD-10 and ICD-9 billing

codes for aortic atherosclerosis (I70), peripheral vascular disease (I73.8, I73.9), and operative

procedures including amputation of leg (X09.3-5), bypass of artery of leg (L21.6, L51.3, L51.6,

L51.8, L59.1-8), endarterectomy or angioplasty of leg artery (L52.1-2, L54.1,4,8, L60.1-2,

L63.1,5), and other transluminal operations on leg arteries or peripheral stent placement

(L63.9,L66.7), as previously described[13]. Additionally, in the UKB self-reported peripheral

vascular disease, leg claudication/intermittent claudication, arterial embolism, femoral-popliteal

leg artery bypass, leg artery angioplasty +/- stent, or amputation of leg were also incorporated

(Data fields 20002, 20004) as performed previously[13]. Coronary artery disease and cerebral

atherosclerosis phenotype definitions for each cohort are detailed in **Tables I and II in the**

supplement. Other atherosclerotic conditions were defined using the Phecode Map 1.2[14] ICD-9

(https://phewascatalog.org/phecodes) and ICD-10 (https://phewascatalog.org/phecodes_icd10)

phenotype groupings for "abdominal aortic aneurysm", "aortic aneurysm", "other aneurysm",

"chronic vascular insufficiency of intestine", "acute vascular insufficiency of intestine",

"atherosclerosis of renal artery". The composite atherosclerosis phenotype was created by

combining all analyzed atherosclerosis phenotypes (including PAD, coronary artery disease,

cerebral atherosclerosis, abdominal aortic aneurysm, aortic aneurysm, other aneurysm, chronic

vascular insufficiency of intestine, acute vascular insufficiency of intestine, and atherosclerosis

of renal artery) into one phenotype, whereby the first instance across all of these phenotypes was

used to determine time of first diagnosed atherosclerotic disease for survival analysis. Other

phenotypic covariates (never/prior/current smoking status, hypertension, hyperlipidemia,

principal components of ancestry, etc.) were used as previously defined[15].

Association Analysis

In the UKB and MGBB a traditional cox-proportional hazards model was utilized using the

Survival package in R-3.5 adjusting for age, age^2, sex, smoking status, normalized Townsend

deprivation index as a marker of socioeconomic status (only available in UKB), and the first ten

principal components of genetic ancestry. Demographic and clinical characteristics found to

differ between individuals with and without CHIP were tested using chi-squared (categorical)

and Wilcoxon-rank sum (continuous) tests with a two-tailed $P < 0.05$ determining significance.

Sensitivity analysis including other covariates (normalized BMI, prevalent hypertension,

prevalent Type 2 diabetes, and prevalent hyperlipidemia) was not found to significantly change

associations with PAD in the UKB (**Figure I in the supplement**). Additional sensitivity

analyses were utilized in the UKB including propensity score adjustment, as well as a marginal

structural cox proportional hazards model estimated through stabilized inverse-probability-

treatment-weight (IPTW)[16] to estimate the total causal effect of CHIP on PAD. Further details of

propensity score methods and stabilized IPTW analysis are described in the supplementary

appendix. For our primary outcome PAD, results were combined across the UKB and MGBB

using an inverse-variance weighted fixed effects meta-analysis, a two tailed association P < 0.05

determined statistical significance. In our secondary analysis of CHIP with 10 additional,

incident atherosclerotic diseases, a two-tailed Bonferroni p-value threshold of P<0.05/10=0.005

was used to declare statistical significance.

Mice

Animal experiments followed protocols approved by the Institutional Ethics Committee

at the Centro Nacional de Investigaciones Cardiovasculares and conformed to EU Directive

86/609/EEC and Recommendation 2007/526/EC regarding the protection of animals used for

experimental and other scientific purposes, enforced in Spanish law under Real Decreto

1201/2005. All mice were maintained on a 12-h light/dark schedule in a specific pathogen-free

animal facility in individually ventilated cages and given food and water ad libitum. C57Bl/6J

Trp53-/- mice were obtained from the Jackson Laboratory. *Ldlr*-/- mice carrying the CD45.1

isoform of the CD45 hematopoietic antigen were generated by crossing LDLR-KO mice from

the Jackson Laboratory and B6.SJL-*PtprcaPepcb*/BoyCrl mice from Charles River Laboratories.

Competitive bone marrow transplantation and atherosclerosis induction in mice

CD45.1+ *Ldlr*-/- recipients were transplanted with suspensions of BM cells containing 20%

CD45.2+ *Trp53*-/- cells and 80% CD45.1+ *Trp53*+/+ cells (20% KO-BMT mice) or 20 %

CD45.2+ *Trp53*+/+ cells and 80% CD45.1+ *Trp53*+/+ cells (20% WT-BMT mice) similar to

previous studies[17] (**Figure II in the supplement**). BM cells were isolated from femurs and tibias

of donor mice after euthanasia. Recipient *Ldlr*-/- mice were exposed to two doses of 450 rad

three hours apart. After the second irradiation, each recipient mouse was injected

with 10^7 BM cells i.v. Water was supplemented with antibiotics for 7 days before transplant and

for 14 days post-transplant. Mice that did not recover full pre-irradiation body weight 28 days

after transplant were excluded from further analysis. Starting four weeks after BMT, mice were

fed a high fat high cholesterol (HF/HC) Western diet (Harlan-Teklad, TD.88137, Adjusted

Calories Diet; 42% from fat, 0.2% cholesterol) to promote hypercholesterolemia and the

development of atherosclerosis. Mice were maintained on a HF/HC diet for 9 weeks

Quantification of aortic atherosclerosis burden in mice

Mice were euthanized and aortas were removed after in situ perfusion with phosphate-buffered

saline injected through the left ventricle of the heart. Tissue fixation was achieved by immersion

in 4% paraformaldehyde in PBS overnight at 4°C. Aortic tissue was then dehydrated and

embedded in paraffin for sectioning. Histological sections comprising the aortic root as

determined by the location of the aortic valve leaflets were cut at a thickness of 4 μm or 6 μm.

An operator who was blinded to genotype quantified plaque size in aortic root sections by

computer-assisted morphometric analysis of microscopy images. For each mouse, atherosclerotic

plaque size in aortic root cross-sections was calculated as the average of 5 independent sections

separated by ∼16μm. Atherosclerotic plaque composition was examined by

immunohistochemical techniques. Vascular smooth muscle cells were identified with an alkaline

phosphatase-conjugated mouse anti-smooth muscle α-actin (SMA) monoclonal antibody (clone

1A4, SIGMA) and Vector Red Alkaline Phosphatase Substrate (Vector Laboratories).

Macrophages were detected with a rabbit anti-Mac2 monoclonal antibody (Santa Cruz

Biotechnologies), a biotin-conjugated goat anti-rat secondary antibody and streptavidin-HRP,

DAB substrate (all from Vector Laboratories), with hematoxylin counterstaining. Collagen

content was determined by a modified Masson's trichrome staining. Microscopy images were

analyzed using ImageJ software using the Color Deconvolution plugin. Plasma was collected in

EDTA-coated tubes and cholesterol levels were determined using an enzymatic assay

(Cholesterol E, WAKO Diagnostics).

Flow cytometry analyses of blood and tissue samples.

Peripheral blood was obtained from the facial vein and collected into EDTA-coated tubes. Bone

marrow cells were flushed out of two femurs and two tibias per mouse. Aortic arches were

digested for 45 minutes at 37°C in RPMI containing 10% FBS and 0.25 mg/ml Liberase TM

(Roche Life Science). Red blood cells were lysed in all samples by treatment with 1X Red Blood

Cell Lysis Buffer (eBioscience ThermoFisher) for 5 minutes on ice. Bone Marrow lineage-

negative cells were defined as negative for CD11b, Gr-1, Ter119, B220, CD3e and CD127. Bone

marrow HSPCs were defined as Lineage-, c-Kit+, Sca1+. Blood classical monocytes were

identified as CD45+, CD115^{Hi}, CD43^{Lo}, Ly6c^{Hi}; patrolling monocytes, as CD45+, CD115^{Hi},

CD43^{Hi}, Ly6c^{Lo}; neutrophils, as CD45+, CD115^{Int}, Ly6g+; T lymphocytes, as CD45+, CD115-,

B220-, CD3+; B lymphocytes, as CD45+, CD115-, CD3-, B220+; and aortic macrophages, as

CD45+, CD3-, Ly6g-, CD11B+, F4/80Hi. Gating strategies can be found in our previous

publications[17, 18]. Samples were stained with combinations of biotinylated and/or fluorescently

labeled antibodies in PBS with 1% FBS for 30 min on ice. The following fluorescent antibodies

were used for staining and flow cytometry analysis: eFluor450-conjugated anti-CD45.2, FITC-

conjugated anti-CD45.2, Pe-Cy7-conjugated anti-CD45.1, FITC-conjugated anti-CD11b,

eFluor450-conjugated anti-CD11B, PE-conjugated anti-CD115, PE-eFluor610-conjugated anti-

CD3, FITC-conjugated anti-CD4 (from eBioscience); APC-Cy7-conjugated anti- B220, PerCP-

Cy5.5-conjugated anti-Ly6G, BV510-conjugated anti-Ly6G, BV711-conjugated anti-CD43, PE-

Cy7-conjugated anti-c-Kit, AlexaFluor647-conjugated anti-Sca-1 (from BD Biosciences); PE-

conjugated anti-F4/80 (from R&D Systems); PerCP-Cy5.5-conjugated anti-CD45.1, BV510-

conjugated anti-CD8a, PerCP-Cy5.5-conjugated anti-mouse Ki-67 (from BioLegend).

Fixation/permeabilization for Ki-67 intracellular staining was achieved using commercially

available kits following manufacturer's instructions (Foxp3 Transcription Factor Staining Buffer

Set, eBioscience ThermoFisher). Dead cells were excluded from analysis by DAPI staining in

unfixed samples and by LIVE/DEAD Fixable Near-IR staining (ThermoFisher Scientific) in

fixed samples. BD LSRFortessa and BD FACSymphony Cytometers (BD Bioscience) were used

for data acquisition. Data were analyzed with FlowJo Software.

Murine macrophage culture and cell cycle analysis

Bone marrow-derived macrophages (BMDM) were obtained from suspensions of femoral BM

and differentiated for 7 days in the presence of RPMI Medium supplemented with antibiotics,

10% fetal bovine serum and 100 ng/ml MCSF. For cell-cycle analysis, MCSF concentration in

cell culture medium was decreased to 5 ng/ml for 48h to induce progressive synchronization of

macrophages in G0 phase (i.e. quiescence) and cell cycle re-entry was induced by treatment with

100 ng/ml MCSF. Macrophages were trypsinized and collected by centrifugation for 5 minutes at

300g. After fixation in 80% ethanol for 1 h at -20ºC, cells were incubated for at least 30 minutes

with 50 μg/mL propidium iodide containing 0.25 mg/mL RNAse A (both from SIGMA).

Labelled cells were analyzed in a BD LSRFortessa flow cytometer BD Bioscience and DNA

histograms were fitted into cell cycle distributions using ModFit 3.0 software (Verity Software

House).

Gene expression analysis by quantitative real-time PCR (qPCR) and Western Blot.

Total RNA from aortic arch tissue was isolated using Trizol reagent and RNeasy kits (QIAGEN).

RNA (1 µg) was reverse transcribed with High-Capacity cDNA Reverse Transcription Kit

(Applied Biosystems) and qPCR was performed with SYBR® Green PCR Master Mix (Applied

Biosystems) in a AB7900 Real time PCR system. Results were analyzed with the ΔΔCt method.

The average of 36B4 and β-actin was used as reference for normalization. Primer sequences can

be found in our previous publication[17]. For Western Blot analysis of protein levels, protein

extracts from cultured macrophages were obtained using ice-cold lysis buffer (20mM Tris-HCl

pH 7.5, 150 mM NaC, 1 mM NA2EDTA, 1 mM EGTA, 1% Triton) supplemented with protease

and phosphatase inhibitors (Roche Applied Science). Equal amounts of protein lysates were

resolved by SDS-PAGE and the following antibodies were used for immunoblotting: anti-p53

(Cell Signaling, #32532S, dil 1/1000) and HRP anti-alpha tubulin (AbCam, #ab40742, dil

1/2000). An ImageQuant LAS 4000 biomolecular imaging system (GE Healthcare) was used for

image acquisition and the ImageJ software was used for band densitometric analysis.

Statistical analysis of data in experimental studies

Data are shown as mean ± SEM unless otherwise stated. Statistical significance of differences in

experiments with two groups and only one variable was assessed by unpaired Student's t tests

(with Welch correction for unequal variance when appropriate) or Mann-Whitney U Tests.

Differences in experiments with more than one independent variable were evaluated by two-way

analysis of variance (ANOVA) with post-hoc Sidak's multiple comparison tests. All statistical

tests were performed using GraphPad Prism software (GraphPad Software Inc.).

Results

Study Cohorts and Risk Of Hematologic Malignancy

After excluding individuals with a known history of hematologic malignancy at enrollment, we

identified 37,657 unrelated individuals from the UKB and 12,465 individuals from MGBB with

whole exome sequencing data available for downstream analysis. Using a previously validated

somatic variant detection algorithm[10], we identified 2,194 (5.8%) and 657 (5.4%) CHIP carriers

in the UKB and MGBB, respectively (**Table III in the supplement**). Demographic and clinical

characteristics of these individuals, stratified by CHIP status, are depicted in **Table IV in the**

supplement. CHIP carriers tended to be older, male, previous smokers, and have a history of

coronary artery disease, hypertension, and hyperlipidemia (two-tailed chi-squared and Wilcoxon-

rank sum P< 0.05).

We first replicated known CHIP associations[10] with white blood cell (Beta 0.09 SD; 95%

CI 0.05-0.13; P=1.6×10^{-5}), monocyte (Beta 0.05 SD; 95% CI 0.01-0.09; P=0.009), neutrophil

(Beta 0.10 SD; 95% CI 0.06-0.14; P=2.1×10^{-6}), and platelet counts (Beta 0.07 SD; 95% CI 0.03-

0.11; P=0.0005) in UKB, with larger CHIP clone size as measured by variant allele fraction

(VAF) having stronger effects on blood counts (**Figure III in the supplement**). Consistent with

the existing literature[5, 10], CHIP also associated with incident hematologic malignancy (HR 2.20;

95% CI 1.70-2.85; P=1.8×10^{-9}) - specifically for acute myeloid leukemia (HR 8.08; 95% CI

4.36-14.97; P=3.2×10^{-11}), myeloproliferative neoplasms (HR 5.89; 95% CI 3.69-9.89; P=9.7×10^{-14}

), and polycythemia vera (HR 12.37; 95% CI 4.85-31.54; P=1.4×10^{-7}). This risk increased with

larger VAF (**Figure IV in the Supplement**).

CHIP and Incident PAD Risk

We next tested the association of CHIP status with incident PAD. Using available electronic

health record (EHR) data and a previously validated PAD definition[13], we identified 338 and 419

incident PAD cases in UKB and MGBB, respectively. CHIP associated with a 58% increased

risk of incident PAD in the UKB (HR_{UKB} = 1.58, 95% CI: 1.11-2.25; P=0.01, **Figure 1**), results

that were replicated in MGBB (Overall HR = 1.66, 95% CI: 1.31-2.11; P=$2.4x10^{-5}$). We then

sought to evaluate whether those with larger CHIP clone sizes (i.e., higher VAF) had greater risk

for PAD, as larger CHIP clones associate more strongly with adverse clinical outcomes[6]. We

observed a graded relationship between CHIP VAF and PAD, as those with a VAF > 10% had

even greater risk for an incident PAD event (Overall HR = 1.97, 95% CI: 1.44-2.71; P=$2.3x10^{-5}$,

Figure 1). Additional sensitivity analyses, including propensity score adjustment and a marginal

structural Cox proportional hazards model estimated through stabilized inverse-probability-

treatment-weight revealed similar results in the UKB (**Figure V in the supplement**). Subsequent

analyses showed no significant interaction between CHIP status and either age, sex, or smoking

status on incident PAD risk.

CHIP and Incident Atherosclerosis Across Multiple Vascular Beds

We next assessed whether CHIP was associated with 9 other incident atherosclerotic

diseases across multiple vascular beds. Using EHR-based disease definitions[19], we tested the

association of CHIP with atherosclerotic disease across the mesenteric (acute and chronic),

coronary, and cerebral vascular beds, as well as with aneurysmal disease (aortic and any other

aneurysm). We observed significant associations for coronary artery disease (HR 1.40, 95% CI:

1.20 to 1.63; P=$1.9x10^{-5}$), any aortic aneurysm (HR 1.74; 95% CI: 1.21 to 2.51; P=0.0028), other

aneurysms (HR 1.70; 95% CI: 1.23 to 2.34; P=0.0013), and chronic mesenteric ischemia (HR

9.12; 95% CI: 2.34 to 35.63; P=0.0015) across both cohorts, with directionally consistent effect

estimates observed for all the tested phenotypes (**Figure 2a**). These associations were

consistently stronger for large CHIP clones (**Figure VI in the supplement)**. We then created a

composite, incident atherosclerosis outcome combining all nine atherosclerotic phenotypes

("pan-arterial atherosclerosis", **Table V in the Supplement**). CHIP associated with this

combined incident pan-arterial atherosclerosis endpoint (HR 1.31, 95% CI: 1.14 to 1.49,

P=9.7×10^{-5}), again with stronger effects conferred by large CHIP clones (HR 1.45; 95% CI: 1.20

to 1.75; P=0.00013) (**Figure 2b,c**).

Gene-specific analyses of CHIP with incident atherosclerotic diseases

Next, we sought to understand whether the clonal hematopoiesis putative driver gene

differentially affected the risk of acquiring atherosclerosis. Previous work has focused primarily

on the epigenetic regulators *DNMT3A* and *TET2*[3, 17], and whether DDR CHIP confers an

increased risk of atherosclerosis is unknown. We stratified the CHIP-PAD and CHIP pan-arterial

atherosclerosis analyses by putative driver genes and specific mutations - focusing on *DNMT3A*,

TET2, *ASXL1*, *JAK2*, the DDR genes *PPM1D* and *TP53*, and mutations that specifically disrupt

splicing factor genes *(LUC7L2, PRPF8, SF3B1, SRSF2, U2AF1,* and *ZRSR2)*[20]. We observed an

association of CHIP with PAD across the four common CHIP genes (*DNMT3A*, *TET2*, *ASXL1*,

and *JAK2*), with significant heterogeneity of incident PAD effect sizes across the CHIP genes

($P_{heterogeneity}$ = 0.03) (**Figure 3a**). This heterogeneity persisted in sensitivity analysis after

excluding *JAK2* carriers ($P_{heterogeneity}$ = 0.046). These data also revealed the novel finding that

DDR *TP53* and *PPM1D* CHIP associates with incident PAD (HR 2.72; 95% CI: 1.20 to 1.75;

P=0.00013) and incident CAD (HR 2.51; 95% CI: 1.52-4.14; P=0.00032), with a stronger effect

on PAD conferred by *TP53* (HR 4.98; 95% CI: 1.23-20.09; P=0.024, **Figure 3a-c).** Similar

findings were observed for the incident pan-arterial atherosclerosis outcome when stratifying by

putative driver gene (**Figure VII in the supplement**). Further sensitivity analysis for DDR-

CHIP and incident PAD when excluding solid organ malignancy did not significantly change the

associations ($P_{heterogeneity} > 0.05$).

Atherosclerosis development in p53-/ CHIP mice

Based on our gene specific findings, we next further characterized the effects of reduced function

of hematopoietic p53 in atherosclerotic mice. To mimic CHIP and test whether the expansion of

p53-deficient hematopoietic cells contributes to atherosclerosis, a competitive bone marrow

transplantation (BMT) strategy was used to generate atherosclerosis-prone *Ldlr*-/- chimeric mice

carrying 20% *Trp53*-/- hematopoietic cells (20% KO-BMT mice). These mice then consumed a

high fat/high cholesterol diet for 9 weeks to induce atherosclerosis development. To distinguish

donor *Trp53*-/- and *Trp53*+/+ cells in this experimental setting, *Trp53*+/+ cells were obtained

from mice carrying the CD45.1 variant of the CD45 hematopoietic antigen, whereas *Trp53*-/-

cells were obtained from mice carrying the CD45.2 variant of this protein. Control mice (20%

WT-BMT) were transplanted with 20% CD45.2+ *Trp53*+/+ cells and 80% CD45.1+ *Trp53*+/+

cells (**Figure 4a and Figure II in the supplement**). Flow cytometry analysis of CD45.2+ blood

cells established that this BMT strategy led to a modest, but significant expansion of donor

Trp53-/- BM-derived cells compared to *Trp53*+/+ cells in both BM hematopoietic

stem/progenitor cells (HSPCs) and circulating white blood cells (**Figure 4B,C**), consistent with

previous studies[21-23]. Transplanted *Trp53*-/- BM cells expanded into all blood cell lineages to a

similar extent, but this relative expansion did not affect absolute blood cell counts (**Figure VIII**

in the supplement). Having validated this mouse model of p53 CHIP based on a competitive

BMT strategy, we next assessed whether this phenomenon affects the development of

atherosclerosis or related metabolic abnormalities. The presence and expansion of *Trp53*-/- cells

led to a significant ~40% increase in plaque size in the aortic root of male *Ldlr*-/- mice (**Figure**

4D), without affecting body weight, spleen weight or serum cholesterol levels (**Figure VIII in**

the supplement, C-E). Similar results were obtained in female *Ldlr*-/- mice (**Figure IX in the**

supplement). In contrast to previous work on *DNMT3A/TET2* CHIP, the expansion of p53-

deficient cells[12, 17, 18, 24, 25] did not affect the expression of the pro-inflammatory cytokines IL-6

and IL-1β in the atherosclerotic aortic wall (**Figure X in the supplement**).

Proliferation and expansion of p53-deficient macrophages in the murine atherosclerotic aorta

Increased atherogenesis in mice carrying *Trp53*-/- cells was paralleled by a substantial increase

in plaque macrophage content, as assessed by immunohistological staining of Mac2, with no

significant changes in other cell components (**Figure 5A**), suggesting a contribution of increased

arterial macrophage burden to accelerated atherosclerosis in conditions of p53 CHIP. Flow

cytometry analysis of matched samples from blood and digested atherosclerotic aortae from

20% KO-BMT mice revealed substantially higher chimerism in aortic macrophages (~76%

Trp53-/-) than in blood classical monocytes (~48%), the major source of plaque macrophages

(**Figure 5B**). This expansion of p53-deficient macrophages within the vascular wall was

paralleled by a 2-fold increase in the frequency of proliferating cells within the CD45.2+ *Trp53*-

/- aortic macrophage population compared to CD45.2+ *Trp53*+/+ macrophages, as assessed by

flow cytometry analysis of the proliferation-related antigen Ki-67 (**Figure 5C).** Consistent with

our observations *in vivo*, cultured *Trp53*-/- macrophages exhibit accelerated mitotic cell cycle

progression, with a >2-fold increase in the percentage of S-phase cells upon stimulation with

macrophage colony stimulating factor (MCSF), a major determinant of plaque macrophage

proliferation[26] (**Figure 5D**). *Trp53* expression analysis suggests a central role of p53 in the

normal regulation of macrophage cell cycle progression, as p53 was expressed in quiescent

macrophages at the transcript and protein level and further induced after MCSF stimulation

(**Figure 5E,F**). Furthermore, p53-deficient macrophages exhibited major changes in the

expression of pivotal regulators of cell cycle entry and progression, such as *Cdkn1a*/p21^{Cip1} and

Cyclin B1 (**Figure 5G**).

Discussion

This study combined exome sequencing data across two biobanks to detect somatic

mutations in over 50,000 individuals and observed that the presence of CHIP was significantly

associated with an increased risk of developing PAD and atherosclerosis across multiple arterial

beds. Increased risk was differentially observed across CHIP driver genes with evidence of a

graded relationship with CHIP VAF, with large CHIP clones conferring greater risk of disease.

Lastly, analysis of p53 CHIP using a BMT murine model showed increased aortic atherosclerotic

plaque among p53 CHIP carriers accompanied by expansion of plaque macrophages, supporting

a direct contribution of p53-mutant hematopoietic cells to accelerated atherogenesis.

These findings permit several conclusions. First, in humans, CHIP appears to promote

atherosclerosis across the entire arterial system. Previous work linked CHIP with increased risk

of coronary artery disease and early-onset MI[2, 3]. We build on these findings by demonstrating

that CHIP is also associated with PAD, and a composite pan-arterial atherosclerosis outcome

reflective of an increased burden of atherosclerosis throughout the human arterial system. In

addition, we observed suggestive CHIP associations with aneurysmal degeneration of the aorta.

The genetic and epidemiologic risk factors underlying atherosclerotic occlusive disease and

AAA overlap considerably[27], and substantial evidence implicates inflammation and macrophage

infiltration in driving this aortic disease[28]. The observed link between CHIP and aneurysmal

disease warrants further investigation in future studies.

Second, DDR gene CHIP appears to confer an increased risk of atherosclerotic

cardiovascular disease. In previous work, Jaiswal et al demonstrated an increased risk of

coronary artery disease among individuals with CHIP through *DNMT3A, TET2, ASXL1,* and

JAK2 somatic driver mutations[3]. DDR CHIP is often observed among individuals following

cytotoxic chemotherapy for the treatment of malignancy and has been linked to the development

of therapy-related myeloid neoplasms, but limited evidence is available to inform clinical

decision making regarding whether DDR CHIP carriers have increased risk of cardiovascular

disease. The current study demonstrates that CHIP related to DDR-genes (*TP53, PPM1D*)

confers an increased risk of developing atherosclerosis. These findings lend human genetic

support to the concept that post-cytotoxic chemotherapy patients may benefit from surveillance

for atherosclerotic conditions in addition to therapy-related myeloid neoplasms.

Third, CHIP related to *TP53* mutations appears to drive atherosclerosis risk via expansion

of p53-deficient macrophages in occlusive plaque lesions. Previous experimental studies

assessed the role of p53 in atherogenesis using mice engineered to exhibit gain or loss of

function of p53 in the whole body or in specific cell types, with a variety of results[29-35]. Here we

demonstrate that carrying a fraction of p53-deficient blood cells is sufficient to accelerate

atherosclerosis development, as these cells have a selective advantage to expand, both in HSPCs

within the BM and in macrophages within the arterial wall, leading to increased macrophage

burden in the atherosclerotic plaque. Mechanistically, p53-deficient macrophage expansion

seems related to increased proliferation, a major driver of macrophage burden in atherosclerotic

plaques[36]. Although p53 expression is typically induced by DNA damage or other kinds of

cellular stress, we found that it is expressed in resting conditions in cultured macrophages and

further induced by mitogenic stimulation, suggesting a physiological role in the regulation of

macrophage cell cycle progression. Accordingly, p53-deficient macrophages exhibited

accelerated cell cycle kinetics. Overall, these experimental findings provide support to the notion

that *TP53* CHIP mutations contribute directly to accelerated atherosclerosis and highlight major

differences in the mechanisms underlying accelerated atherosclerosis in CHIP driven by

mutations in *TP53* or epigenetic regulators. Previous murine studies on *Tet2* CHIP showed that

TET2-deficient cells expand in bone marrow and blood, but not in the atherosclerotic plaque. In

contrast, we found that p53 exhibits a double competitive advantage, expanding in both the BM

and arterial wall, which suggests that small *TP53*-mutant blood clones may be sufficient to

accelerate atherosclerosis development. Evaluating this possibility will require additional studies

using high sensitivity sequencing strategies. Furthermore, in contrast to previous reports related

to *DNMT3A/TET2* CHIP[12, 17, 18, 24, 25], we did not observe a significant effect of p53 deficiency on

the expression of the pro-inflammatory cytokines IL-1β and IL-6. These results are consistent

with previous human data showing that circulating levels of pro-inflammatory cytokines are

significantly increased in carriers of CHIP driven by mutations in these epigenetic regulators, but

not in carriers of mutations in *TP53* or *PPM1D*[10]. These mechanistic differences between *TP53*-

CHIP and *DNMT3A/TET2*-CHIP require consideration when designing preventive care strategies

targeting the effects of CHIP on atherosclerosis. Thus, while the pathogenic effects of TET2-

CHIP may be prevented by targeting IL-1β-driven inflammation[17], accelerated atherosclerosis

associated with *TP53* mutations may be better tackled by other strategies. Additional

experimental and clinical studies should evaluate these opportunities for personalized medicine

in the context of CHIP.

Lastly, a recent publication has generated a novel hypothesis regarding the relationship

between CHIP and atherosclerosis[37]. In their analysis, Heyde et al. suggest that CHIP may be a

symptom of the atherosclerosis trait complex (the interplay of chronic inflammation,

hyperlipidemia, and arterial plaque), rather than a causal risk factor, based on murine and human

observations that atherosclerosis may accelerate HSC proliferation and somatic evolution. While

their study engenders an intriguing hypothesis, there are several observations in the literature and

in our current study that we believe do not support this interpretation. Firstly, in the Heyde et al.

study, *Ldlr*-null mice irradiated and transplanted with bone marrow of *Tet2* -/- mice that were fed

an atherogenic diet demonstrated greater *Tet2* -/- neutrophil and monocyte expansion than

similar mice fed normal chow. However, in marked contrast, we previously showed that *Tet2*-/-

cells expand similarly when *Ldlr*-null mice are fed either a high cholesterol diet or normal

chow[17]. Furthermore, in our prior work, the expansion of *Tet2*-/- cells was completely unaffected

by treatment with a pharmacological NLRP3 inhibitor, even though this inhibitor led to a 2-fold

decrease in atherosclerotic plaque size[17]. Secondly, in our current analysis of the pan-arterial

atherosclerosis endpoint, CHIP was associated with incident atherosclerotic events among a pool

of individuals without any history of atherosclerosis at baseline - suggesting that CHIP precedes

clinically significant occlusive disease. Thirdly, Heyde et al. state that the uniform hazard ratios

observed for the CHIP-coronary artery disease association provide supportive evidence for the

notion that atherosclerotic disease precedes the development of clonal hematopoiesis. However,

in our study we identify significant heterogeneity of incident PAD effect sizes when stratifying

by CHIP genes, as well as a dose-response relationship between CHIP clone size (or VAF) and

incidence of atherosclerosis, suggesting that CHIP genes vary in their effect on incident PAD

risk, and that expanded CHIP variants have a stronger influence on future atherosclerotic risk.

Thus, given the 1) association with incident atherosclerotic disease, 2) dose-response relationship

with CHIP clone size and heterogeneity by CHIP gene, and 3) that *TP53*, *TET2*, and *JAK2*[38]

appear to drive atherosclerosis through disparate mechanisms, clonal hematopoiesis acting as a

causal risk factor appears to be a more parsimonious explanation to unify these findings.

Several limitations merit mention. First, our PAD and cardiovascular disease phenotypes

are based on EHR data and may result in misclassification of case status. Such misclassification

would likely reduce statistical power for discovery and on average bias results toward the null.

Second, selection bias from differential loss-of-follow up, volunteer bias, and missingness in

covariates may be present given the nature of the genetic biobanks used in this study. Third,

while we maximized the number of participants in our analysis of CHIP and additional

atherosclerotic diseases, it may still have been underpowered for certain phenotypes. Lastly, the

cohorts in these studies are largely of European ancestry; while prior reports have not observed

significant phenotypic differences in CHIP associations by ancestry[5, 12], further epidemiological

studies in ethnically diverse individuals are required to ensure that this is the case for PAD as

well.

In conclusion, CHIP is associated with incident atherosclerosis in multiple vascular beds,

with murine evidence of increased plaque among *TP53* CHIP carriers through an expansion of

plaque macrophages (**Figure 6**). The observations presented here expand insight into CHIP-

mediated atherosclerosis. The novel finding that DDR gene CHIP plays a particular role in PAD

raises new questions regarding the mechanisms of regional heterogeneity of atherosclerotic

involvement in face of systemic exposure to traditional risk factors such as dyslipidemia,

hypertension, and smoking.

a.

Association of CHIP with Incident Peripheral Artery Disease	HR	95% CI	P	Cases (N)	Controls (N)	Cases with CHIP (N)	Controls with CHIP (N)
CHIP							
UK Biobank	1.58	[1.11; 2.25]	0.01	302	37,106	36	2,143
MGB Biobank	1.74	[1.26; 2.39]	0.00068	373	11,875	46	596
Overall	1.67	[1.32; 2.11]	2.2e−05				
Large CHIP							
UK Biobank	2.25	[1.45; 3.49]	0.00028	302	37,106	22	879
MGB Biobank	1.71	[1.09; 2.68]	0.02	373	11,875	21	287
Overall	1.97	[1.44; 2.69]	2.4e−05				

b.

Number at risk

Strata			
Large CHIP	904	895	457
Small CHIP	1285	1281	679
No CHIP	35329	35214	19598

c.

Figure 1. CHIP and incident PAD risk. a) Association of CHIP and large CHIP (VAF>10%) carrier state with incident PAD events in the UK Biobank (UKB) and Mass General Brigham Biobank (MGBB). Results were combined using an inverse-variance weighted fixed effects meta-analysis. b) Cumulative proportion of individuals developing PAD stratified by CHIP VAF clone size category in the UK Biobank. c) Fraction of individuals developing incident PAD by CHIP VAF in the UK Biobank. CHIP = clonal hematopoiesis of indeterminate potential; VAF = variant allele fraction; PAD = peripheral artery disease

Figure 2. CHIP and incident pan-arterial atherosclerosis risk. a) Association of CHIP with 9 incident atherosclerotic diseases separately and combined in a 'Pan-arterial atherosclerosis' phenotype in the UKB, MGBB, and meta-analyzed across both studies ("Overall"). b) Cumulative risk of incident atherosclerosis across the composite 'pan-arterial atherosclerosis' phenotype stratified by no CHIP, small CHIP (VAF<10%), and large CHIP (VAF≥10%) carrier state in the UK Biobank. c) Association of CHIP VAF with fraction of individuals developing pan-arterial atherosclerosis in the UK Biobank. CHIP = clonal hematopoiesis of indeterminate potential; VAF = variant allele fraction; PAD = peripheral artery disease

Figure 3: Gene-specific association of CHIP with incident peripheral artery disease (PAD).
a) CHIP-PAD association analyses stratified by putative CHIP driver gene. Results following
meta-analysis across the UKB and MGBB are shown. b) Gene-specific comparison of HR and
95% CI for hematologic malignancy (x-axis) and PAD (y-axis) in the UKB. c) Association of
DDR CHIP (*PPM1D or TP53*) with incident peripheral artery disease, coronary artery disease,
and pan-vascular atherosclerosis. Results across UK Biobank and MGB Biobank were combined
using an inverse-variance weighted fixed effects meta-analysis. CHIP = clonal hematopoiesis of
indeterminate potential; DDR = DNA-damage repair; VAF = variant allele fraction; PAD =
peripheral artery disease

Figure 4: Accelerated atherosclerosis in a murine model of *TP53* mutation-driven CHIP.
a) Summary of the competitive BMT approach and the timeline of these studies. 20% KO-BMT male mice and 20% WT-BMT controls were fed a high-fat/high-cholesterol (HF/HC) diet for 9 weeks, starting 4 weeks after BMT (n=10 20% WT-BMT, n=7 20% KO-BMT, unless otherwise noted). b) Percentage of CD45.2+ cells in the bone marrow HSPC population (Lin- Sca1+ cKit+ cells) after 9 weeks on HF/HC diet (13 weeks post-BMT), evaluated by flow cytometry (n= 5 20% WT-BMT, n=6 20% KO-BMT). c) Percentage of CD45.2+ in white blood cells, evaluated by flow cytometry (**p<0.01, ***p<0.001). Representative CD45.1/CD45.2 dot plots are shown. d) Aortic root plaque size. Representative images of hematoxylin and eosin-stained sections are shown; atherosclerotic plaques are delineated by dashed lines. Scale bars, 100 μm.

Figure 5: Increased proliferation and expansion of p53-deficient macrophages. a) Plaque composition in 20% KO BMT female mice (n=10) and controls (n=8) quantified as absolute intimal content of macrophages (Mac2 antigen immunostaining), vascular smooth muscle cells (smooth muscle α-actin, SMA immunostaining), collagen (Masson's trichrome staining) and necrotic core (collagen-free acellular regions). Representative images of Mac2- and collagen-stained histological sections of 20% KO BMT mice are shown. b) Percentage of CD45.2+ cells within the aortic macrophage population (CD3-, Ly6g-, CD11B+, F4/80^{Hi}, n = 3 pools of two aortic arches per BM genotype) and blood classical monocytes (CD3-, CD115^{Hi}, Ly6g-, CD43^{Lo}, Ly6c^{Hi}, n=6 per BM genotype) of 20% KO BMT mice and controls, evaluated by flow cytometry. Representative CD45.1/CD45.2 plots of aortic macrophages are shown. c) Percentage of Ki-67+ proliferating cells within the aortic CD45.2+ macrophage population of 20% KO BMT mice and controls (n = 3 pools of two aortic arches per BM genotype), evaluated by flow cytometry. Representative plots are shown. d) % of S-phase cells in cultures of *Trp53*-/- and +/+ murine bone marrow-derived macrophages, evaluated by propidium iodide staining of cellular DNA content and flow cytometry; treatment with MCSF was used to induce cell cycle entry and progression in quiescent G0-synchronized macrophages (a representative experiment with macrophages from n=3 mice per genotype is shown). e, f) qPCR (e) and Western Blot (f) analyses of *Trp53* expression in cultured macrophages after MCSF mitogenic stimulation. p53 protein levels were normalized to α-tubulin. A representative blot is shown. g) Expression of cell cycle regulators *Cdkn1a*/p21^{Cip1} and *Ccnb1*/Cyclin B1 in cultured *Trp53*-/- and +/+ macrophages proliferating asynchronously (Async) or after MCSF stimulation. *p<0.05, **p<0.01, ***p<0.001.

709
710
Figure 6. In this study, we assessed the association of clonal hematopoiesis of indeterminate
potential (CHIP) with myeloid driver mutations with pan-arterial atherosclerosis. CHIP is a
category of age-related somatic variants which are associated with incident leukemia and thought
to be implicated in atherosclerosis primarily by altering macrophage function and promoting
thrombosis. CHIP clones can be characterized by the fraction of blood cells carrying the clone,
referred to as the variant allele fraction (VAF); here we categorized large CHIP clones as
variants with VAF>10%. Across 50,112 individuals from the UK Biobank and Mass-General
Brigham Biobank, we observed that CHIP is associated with increased risk of incident peripheral
and pan-arterial atherosclerosis, with stronger effects conferred by large CHIP clones (HR 1.5x).
In addition, we observed and a novel associations for *TP53* and *PPM1D* CHIP (HR 2.0x). CHIP
was found to be individually associated with a variety of atherosclerotic conditions, with
Bonferroni-significant associations (double-starred, **) identified for peripheral artery disease
(PAD), coronary artery disease (CAD), aortic aneurysm, and chronic mesenteric ischemia. HR
for CHIP are displayed in blue and for large CHIP in purple. Functional analysis was performed
to further investigate the observed TP53-PAD association. *Ldlr*-KO 20% p53 -/- bone-marrow
transplanted mice had a significant increase in plaque size, with significant expansion of p53-
deficient macrophages in plaque (P<0.001) at 12 weeks.
728

731
732

Supplementary Figure I. Association of CHIP and Large CHIP (variant allele fraction>10%)
with PAD in the UKB under 1) unadjusted, 2) sparsely adjusted, and 3) fully adjusted models,
where sparsely adjusted refers to the following covariates: age, age^2, sex, smoking status,
Townsend deprivation index, and the first ten principal components of genetic ancestry, and the
fully adjusted model additionally includes normalized BMI, prevalent hypertension,
hyperlipidemia, and type 2 diabetes as covariates. Given the minimal difference between the
sparsely adjusted and fully adjusted model, the sparsely adjusted model was moved forward for
use in analysis.

774
775
776
777 **Supplementary Figure II.** Competitive bone marrow transplantation approach to generate a
778 murine model of p53 CHIP
779

	Association of CHIP with blood counts (SD)	Beta (SD)	95% CI	P
CHIP				
Neutrophill count		0.096	[0.056; 0.135]	2.1e−06
White blood cell leukocyte count		0.087	[0.047; 0.127]	1.6e−05
Platelet count		0.069	[0.030; 0.107]	0.00052
Monocyte count		0.052	[0.013; 0.091]	0.0093
Basophill count		0.047	[0.007; 0.087]	0.022
Eosinophill count		−0.039	[−0.081; 0.002]	0.061
Reticulocyte count		0.036	[−0.004; 0.077]	0.077
Red blood cell erythrocyte count		0.028	[−0.006; 0.062]	0.1
Lymphocyte count		0.005	[−0.034; 0.045]	0.79
Large CHIP				
Neutrophill count		0.138	[0.078; 0.199]	7.3e−06
White blood cell leukocyte count		0.122	[0.062; 0.183]	7.2e−05
Reticulocyte count		0.086	[0.024; 0.148]	0.0063
Red blood cell erythrocyte count		0.072	[0.020; 0.123]	0.0065
Platelet count		0.079	[0.020; 0.138]	0.0089
Eosinophill count		−0.084	[−0.147; −0.021]	0.0094
Basophill count		0.063	[0.001; 0.124]	0.045
Monocyte count		0.059	[0.000; 0.119]	0.05
Lymphocyte count		0.014	[−0.046; 0.074]	0.64

Supplementary Figure III. Association of CHIP with blood counts among individuals without prevalent hematologic malignancy in the UK Biobank. Blood counts were acquired at time of blood draw for whole exome sequencing. a) Association of CHIP and Large CHIP with normalized blood counts (SD). Associations are adjusted for age, age^2, sex, smoking status, and the first ten principal components of genetic ancestry. b) Association of CHIP variant allele frequency (VAF) with blood counts (in units of 10^9 cells/L). The gray horizontal dotted lines reflect average counts across non-CHIP carriers. The vertical black dotted line reflects the cutoff VAF for Large CHIP (VAF>0.1). CHIP = clonal hematopoiesis of indeterminate potential; VAF = variant allele fraction

825
826
827
a.

Association of CHIP with Incident Disease	HR	95% CI	P	Cases (N)	Controls (N)	Cases with CHIP (N)	Controls with CHIP (N)
CHIP							
Hematologic Malignancy	2.20	[1.70; 2.85]	1.8e−09	478	37,179	69	2,125
Myeloproliforative Neoplasm	5.89	[3.69; 9.39]	9.7e−14	84	37,573	27	2,167
Acute Myeloid Leukemia	8.08	[4.36; 14.97]	3.2e−11	45	37,612	17	2,177
Polycythemia Vera	12.37	[4.85; 31.54]	1.4e−07	19	37,638	8	2,186
Large CHIP							
Hematologic Malignancy	3.45	[2.54; 4.70]	3e−15	478	37,179	46	865
Myeloproliforative Neoplasm	10.62	[6.37; 17.72]	1.4e−19	84	37,573	21	890
Acute Myeloid Leukemia	9.86	[4.58; 21.24]	5e−09	45	37,612	9	902
Polycythemia Vera	22.84	[8.19; 63.72]	2.3e−09	19	37,638	6	905

b.

Supplementary Figure IV: Association of CHIP (a) and VAF (b) with incident hematologic malignancy among individuals without prevalent hematological malignancy in the UK Biobank. Associations are adjusted for age, age^2, sex, smoking status, Townsend deprivation index, and the first ten principal components of genetic ancestry. CHIP = clonal hematopoiesis of indeterminate potential; VAF = variant allele fraction

Supplementary Figure V: Epidemiological causal inference analysis for CHIP on incident peripheral artery disease in the UK Biobank. a) Propensity scores by CHIP and Large CHIP status in the UKB. **b)** Propensity score adjustment and stabilized inverse probability treatment weighting (IPTW) for the CHIP and Large CHIP association with incident PAD in the UKB. CHIP = clonal hematopoiesis of indeterminate potential; VAF = variant allele fraction; PAD = peripheral artery disease

885
886
887
888

Association of Large CHIP with Incident Disease	HR	95% CI	P	Cases (N)	Controls (N)	Cases with CHIP (N)	Controls with CHIP (N)
Peripheral artery disease							
UK Biobank	2.25	[1.45; 3.49]	0.00028	302	37,106	22	879
MGB Biobank	1.71	[1.09; 2.68]	0.02	373	11,875	21	287
Overall	1.97	[1.44; 2.69]	2.4e−05	.			
Coronary artery disease							
UK Biobank	1.44	[1.06; 1.94]	0.018	1,044	35,564	45	833
MGB Biobank	1.56	[1.14; 2.15]	0.0061	858	11,178	41	249
Overall	1.50	[1.20; 1.86]	0.00031				
Any aortic aneurysm							
UK Biobank	2.24	[1.29; 3.88]	0.004	194	37,433	14	895
MGB Biobank	1.19	[0.37; 3.85]	0.77	78	12,127	3	293
Overall	2.00	[1.22; 3.29]	0.0063				
Abdominal aortic aneurysm							
UK Biobank	2.49	[1.29; 4.80]	0.0064	113	37,528	10	900
Overall	2.49	[1.29; 4.80]	0.0064				
Other aneurysm							
UK Biobank	2.46	[1.54; 3.95]	0.00018	244	37,369	19	890
MGB Biobank	1.29	[0.52; 3.18]	0.58	132	11,943	5	283
Overall	2.14	[1.41; 3.26]	0.00036				
Chronic mesenteric ischemia							
MGB Biobank	14.70	[3.34; 64.70]	0.00038	12	12,424	3	310
Overall	14.70	[3.34; 64.70]	0.00038				
Acute mesenteric ischemia							
UK Biobank	1.91	[0.59; 6.24]	0.28	49	37,598	3	908
Overall	1.91	[0.59; 6.24]	0.28				
Cerebral atherosclerosis							
UK Biobank	1.05	[0.69; 1.60]	0.82	623	36,850	23	886
MGB Biobank	1.66	[0.98; 2.82]	0.062	269	11,990	15	288
Overall	1.25	[0.90; 1.74]	0.18				
Pan−arterial atherosclerosis							
UK Biobank	1.55	[1.25; 1.92]	5.9e−05	1,875	34,366	89	780
MGB Biobank	1.14	[0.79; 1.64]	0.48	977	10,488	32	223
Overall	1.43	[1.19; 1.72]	0.00013				

893
894
895
896 **Supplementary Figure VI:** Association of Large CHIP (VAF>10%) with incident pan-arterial
897 atherosclerosis, combined across peripheral artery disease, coronary artery disease, aneurysms,
898 chronic and acute mesenteric ischemia, cerebral atherosclerosis, and renal artery stenosis. CHIP
899 = clonal hematopoiesis of indeterminate potential; VAF = variant allele fraction
900

901
902 **a.**

929 **Supplementary Figure VII:** Association of **a)** CHIP and **b)** Large CHIP genes with incident
930 pan-arterial atherosclerosis, combined across peripheral artery disease, coronary artery disease,
931 aneurysms, chronic and acute mesenteric ischemia, cerebral atherosclerosis, and renal artery
932 stenosis. CHIP = clonal hematopoiesis of indeterminate potential; VAF = variant allele fraction
933
934

935
936

Supplementary Figure VIII: 20% KO-BMT male mice and 20% WT-BMT controls were fed a high-fat/high-cholesterol (HF/HC) diet for 9 weeks, starting 4 weeks after BMT. a) Percentage of CD45.2+ cells in different white blood cell (WBC) lineages in peripheral blood, evaluated by flow cytometry (***p<0.001). b) Absolute counts of main WBC sub-populations in peripheral blood, evaluated by flow cytometry. c) Body weight. d) Spleen weight. e) Total cholesterol level in serum, evaluated by enzymatic methods.

948
949
Supplementary Figure IX. 20% KO-BMT female mice (n=13) and 20% WT-BMT controls
(n=17) were fed a high-fat/high-cholesterol (HF/HC) diet for 9 weeks, starting 4 weeks after
BMT. a) Percentage of CD45.2+ in white blood cells at different timepoints, evaluated by flow
cytometry (***p<0.001). b) Percentage of CD45.2+ cells in different white blood cell (WBC)
lineages in peripheral blood after 9 weeks on HF/HC diet (13 weeks post-BMT), evaluated by
flow cytometry (***p<0.001). c) Aortic root plaque size. Representative images of hematoxylin
and eosin-stained sections are shown; atherosclerotic plaques are delineated by dashed lines.
Scale bars, 100 μm. d) Body weight. e) Spleen weight. f) Total cholesterol level in serum,
evaluated by enzymatic methods.

959
960
961 **Supplementary Figure X.** Aortic arch samples were obtained from HF/HC-fed 20% WT-BMT
962 mice (n=11) or 20% KO-BMT mice (n=10) and gene expression was analyzed by qPCR
963 analysis.

Sources:

1.   Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, Mills JL, Ricco JB,
Suresh KR and Murad MH. Global vascular guidelines on the management of chronic limb-
threatening ischemia. *J Vasc Surg*. 2019;69:3S-125S.e40.
2.   Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC,
Mermel CH, Burtt N, Chavez A, et al. Age-Related Clonal Hematopoiesis Associated with
Adverse Outcomes. *New England Journal of Medicine*. 2014;371:2488-2498.
3.   Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta
N, Gabriel S, Ardissino D, et al. Clonal Hematopoiesis and Risk of Atherosclerotic
Cardiovascular Disease. *New England Journal of Medicine*. 2017;377:111-121.
4.   Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt
HK, Yellapantula V, Miller CA, et al. Age-related mutations associated with clonal
hematopoietic expansion and malignancies. *Nature medicine*. 2014;20:1472-8.
5.   Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, Chambert
K, Mick E, Neale BM, Fromer M, et al. Clonal hematopoiesis and blood-cancer risk inferred
from blood DNA sequence. *N Engl J Med*. 2014;371:2477-87.
6.   Bick AG, Pirruccello JP, Griffin GK, Gupta N, Gabriel S, Saleheen D, Libby P,
Kathiresan S and Natarajan P. Genetic Interleukin 6 Signaling Deficiency Attenuates
Cardiovascular Risk in Clonal Hematopoiesis. *Circulation*. 2020;141:124-131.
7.   Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
Delaneau O, O'Connell J, et al. The UK Biobank resource with deep phenotyping and genomic
data. *Nature*. 2018;562:203-209.
8.   Smoller JW, Karlson EW, Green RC, Kathiresan S, MacArthur DG, Talkowski ME,
Murphy SN and Weiss ST. An eMERGE Clinical Center at Partners Personalized Medicine.
Journal of personalized medicine. 2016;6.
9.   Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, Gonzaga-
Jauregui C, Khalid S, Ye B, Banerjee N, et al. Exome sequencing and characterization of 49,960
individuals in the UK Biobank. *Nature*. 2020;586:749-756.
10.   Bick AG, Weinstock JS, Nandakumar SK, Fulco CP, Bao EL, Zekavat SM, Szeto MD,
Liao X, Leventhal MJ, Nasser J, et al. Inherited causes of clonal haematopoiesis in 97,691 whole
genomes. *Nature*. 2020;586:763-768.
11.   Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC,
Mermel CH, Burtt N, Chavez A, et al. Age-related clonal hematopoiesis associated with adverse
outcomes. *N Engl J Med*. 2014;371:2488-98.
12.   Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta
N, Gabriel S, Ardissino D, et al. Clonal Hematopoiesis and Risk of Atherosclerotic
Cardiovascular Disease. *N Engl J Med*. 2017;377:111-121.
13.   Klarin D, Lynch J, Aragam K, Chaffin M, Assimes TL, Huang J, Lee KM, Shao Q,
Huffman JE, Natarajan P, et al. Genome-wide association study of peripheral artery disease in
the Million Veteran Program. *Nature medicine*. 2019;25:1274-1279.
14.   Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, Zhao J, Carroll R, Bastarache L,
Denny JC, et al. Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development
and Initial Evaluation. *JMIR Med Inform*. 2019;7:e14325.

15.   Zekavat SM, Lin S-H, Bick AG, Liu A, Paruchuri K, Uddin MM, Ye Y, Yu Z, Liu X,
Kamatani Y, et al. Hematopoietic mosaic chromosomal alterations and risk for infection among
767,891 individuals without blood cancer. *medRxiv*. 2020:2020.11.12.20230821.
16.   Hernan MA, Brumback B and Robins JM. Marginal structural models to estimate the
causal effect of zidovudine on the survival of HIV-positive men. *Epidemiology*. 2000;11:561-70.
17.   Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu
CL, Sano S, Muralidharan S, Rius C, et al. Clonal hematopoiesis associated with TET2
deficiency accelerates atherosclerosis development in mice. *Science (New York, NY)*.
2017;355:842-847.
18.   Fuster JJ, Zuriaga MA, Zorita V, MacLauchlan S, Polackal MN, Viana-Huete V, Ferrer-
Pérez A, Matesanz N, Herrero-Cervera A, Sano S, et al. TET2-Loss-of-Function-Driven Clonal
Hematopoiesis Exacerbates Experimental Insulin Resistance in Aging and Obesity. *Cell reports*.
2020;33:108326.
19.   Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, Field JR, Pulley
JM, Ramirez AH, Bowton E, et al. Systematic comparison of phenome-wide association study of
electronic medical record data and genome-wide association study data. *Nat Biotechnol*.
2013;31:1102-10.
20.   Visconte V, M ON and H JR. Mutations in Splicing Factor Genes in Myeloid
Malignancies: Significance and Impact on Clinical Features. *Cancers (Basel)*. 2019;11.
21.   Bondar T and Medzhitov R. p53-mediated hematopoietic stem and progenitor cell
competition. *Cell Stem Cell*. 2010;6:309-22.
22.   Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM,
Deblasio A, Menendez S, et al. p53 regulates hematopoietic stem cell quiescence. *Cell Stem Cell*.
2009;4:37-48.
23.   TeKippe M, Harrison DE and Chen J. Expansion of hematopoietic stem cell phenotype
and activity in Trp53-null mice. *Exp Hematol*. 2003;31:521-7.
24.   Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, Zuriaga MA,
Yoshiyama M, Goukassian D, Cooper MA, et al. Tet2-Mediated Clonal Hematopoiesis
Accelerates Heart Failure Through a Mechanism Involving the IL-1beta/NLRP3 Inflammasome.
J Am Coll Cardiol. 2018;71:875-886.
25.   Abplanalp WT, Cremer S, John D, Hoffmann J, Schuhmacher B, Merten M, Rieger MA,
Vasa-Nicotera M, Zeiher AM and Dimmeler S. Clonal Hematopoiesis-Driver DNMT3A
Mutations Alter Immune Cells in Heart Failure. *Circ Res*. 2021;128:216-228.
26.   Sinha SK, Miikeda A, Fouladian Z, Mehrabian M, Edillor C, Shih D, Zhou Z, Paul MK,
Charugundla S, Davis RC, et al. Local M-CSF (Macrophage Colony-Stimulating Factor)
Expression Regulates Macrophage Proliferation and Apoptosis in Atherosclerosis. *Arterioscler*
Thromb Vasc Biol. 2021;41:220-233.
27.   Klarin D, Verma SS, Judy R, Dikilitas O, Wolford BN, Paranjpe I, Levin MG, Pan C,
Tcheandjieu C, Spin JM, et al. Genetic Architecture of Abdominal Aortic Aneurysm in the
Million Veteran Program. *Circulation*. 2020.
28.   Shimizu K, Mitchell RN and Libby P. Inflammation and cellular immune responses in
abdominal aortic aneurysms. *Arterioscler Thromb Vasc Biol*. 2006;26:987-94.
29.   Boesten LS, Zadelaar AS, van Nieuwkoop A, Hu L, Teunisse AF, Jochemsen AG, Evers
B, van de Water B, Gijbels MJ, van Vlijmen BJ, et al. Macrophage p53 controls macrophage
death in atherosclerotic lesions of apolipoprotein E deficient mice. *Atherosclerosis*.
2009;207:399-404.

30.   Fuster JJ, Fernandez P, Gonzalez-Navarro H, Silvestre C, Nabah YN and Andres V.
Control of cell proliferation in atherosclerosis: insights from animal models and human studies.
Cardiovasc Res. 2010;86:254-64.
31.   Guevara NV, Kim HS, Antonova EI and Chan L. The absence of p53 accelerates
atherosclerosis by increasing cell proliferation in vivo. *Nat Med*. 1999;5:335-9.
32.   Mercer J, Figg N, Stoneman V, Braganza D and Bennett MR. Endogenous p53 protects
vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout
mice. *Circ Res*. 2005;96:667-74.
33.   Merched AJ, Williams E and Chan L. Macrophage-specific p53 expression plays a
crucial role in atherosclerosis development and plaque remodeling. *Arterioscler Thromb Vasc*
Biol. 2003;23:1608-14.
34.   Sanz-Gonzalez SM, Barquin L, Garcia-Cao I, Roque M, Gonzalez JM, Fuster JJ, Castells
MT, Flores JM, Serrano M and Andres V. Increased p53 gene dosage reduces neointimal
thickening induced by mechanical injury but has no effect on native atherosclerosis. *Cardiovasc*
Res. 2007;75:803-12.
35.   van Vlijmen BJ, Gerritsen G, Franken AL, Boesten LS, Kockx MM, Gijbels MJ,
Vierboom MP, van Eck M, van De Water B, van Berkel TJ, et al. Macrophage p53 deficiency
leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. *Circ Res*. 2001;88:780-6.
36.   Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, Gorbatov R,
Sukhova GK, Gerhardt LM, Smyth D, et al. Local proliferation dominates lesional macrophage
accumulation in atherosclerosis. *Nat Med*. 2013;19:1166-72.
37.   Heyde A, Rohde D, McAlpine CS, Zhang S, Hoyer FF, Gerold JM, Cheek D, Iwamoto
Y, Schloss MJ, Vandoorne K, et al. Increased stem cell proliferation in atherosclerosis
accelerates clonal hematopoiesis. *Cell*. 2021;184:1348-1361 e22.
38.   Fidler TP, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T, Liu W, Thomas
DG, Hajebrahimi MA, Pircher J, et al. The AIM2 inflammasome exacerbates atherosclerosis in
clonal haematopoiesis. *Nature*. 2021;592:296-301.
1107